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ABSTRACT
Background: Viral load has been used to diagnose and monitor patients who are being 
treated for chronic hepatitis B (CHB). The Diagnosis methods are molecular-based and 
expensive. Quantitation of hepatitis B surface antigen (HBsAg) by automated chemilu-
minescent micro-particle immunoassay has been proposed to be a surrogate marker. 
Quantitating HBV DNA levels molecularly is expensive; thus, a cheaper laboratory test 
as a surrogate diagnostic marker might simplify our management.
Objectives:We determined whether quantitative HBsAg levels correlate with HBV DNA 
levels in CHB. 
Patients and Methods: In this cross-sectional study, all CHB patients who were referred 
by a gastroenterologist to undergo quantitative HBV DNA assay in a qualified labora-
tory in Mashhad, Iran in 2009 were enrolled, and blood samples was obtained. Pa-
tients who were positive for antibodies to HCV and HDV were excluded. HBV DNA was 
measured by real-time polymerase chain reaction, and serum HBsAg was quantified 
byelectrochemiluminescence assay (Roche Diagnostic).
Results:Of 97 patients, 70 were male (72%) and 27 were female (28%); the mean age was 
39 ± 11 years. Eighty-seven percent wasHBeAg-negative. By Mann-Whitney test,HBSAg 
titer differed significantly between HBeAg-positive and -negative patients (P = 0.001), 
as did HBV DNA levels (P = 0.009). By Spearman test, there was no significant correla-
tion between HBsAg and HBV DNA levels (P= 0.606 and r = 0.53). 
Conclusions:HBeAg-negative patients have higher levels of HBsAg and lower levels of 
HBV DNA. By electrochemiluminescence assay,HBsAg has no significant correlation 
with HBV DNA levels in CHB with predominant genotype D and HBeAg negativity in 
Iran.
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Background 
Chronic hepatitis B is a major global problem, affecting 
more than 350 million chronic Hepatitis B worldwide (1)
and leading to 1 million deaths each year (2) Quantitative 
  Implication for health policy/practice/research/medical education: 
Quantitative detection of HBsAg as one of the new diagnostic methods is discussed recently in many papers. This article opens new 
windows toward basic scientists, clinicians in the field of hepatology and infection diseases.
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levels of HBV DNA, ALT levels, and histological findings 
are three factors to consider when determining HBV treat-
ment. Active viral infection scan be detected by quantify-
ing HBV DNA, but such assays are molecular-based and 
expensive. Considering the distribution of HBV, particu-
larly in developing countries, a cheaper laboratory test 
that can be used as a surrogate marker for the molecu-
lar detection of HBV DNA might make our management 
more practical. Hepatitis B virus is a DNA virus that has 
a circular and partially double-stranded genome, which 
encodes four major proteins—S, P, C, X. HBsAg is the chief 
protein of the viral envelop, and serological assays that 
detect HBsAg have guided the diagnosis of hepatitis B 
infection. We hypothesize that it can be a useful tool for 
managing patients as well.
Recently, the relationship between serum HBsAg con-
centrations and HBV DNA levels in hepatitis B patients 
who are positive for serum HBsAg and HBeAg was exam-
ined. Serum HBsAg concentration was related to HBV 
DNA replication level; nevertheless, it is not feasible to 
use HBsAg concentration to monitor HBV replication 
levels (3). In noncirrhotic patients, HBV DNA and HBsAg 
levels correlate negatively. HBsAg levels are low in HBeAg-
positive patients but higher in HBeAg-negative cases; HBV 
DNA levels are higher in HBeAg-positive patients com-
pared with HBeAg-negative cases (4). In another study, 
however, serum HBsAg levels, using Architect HBsAg QT, 
were higher in HBeAg-positive than in anti-HBe positive 
chronic HBV carriers, correlating with the level of serum 
HBV DNA (5). Quantitative measurements of HBsAg titer 
constitute a simple and economical reference for HBV 
replication in HBV carriers as well (6). Previous studies 
have suggested that quantitative hepatitis B surface an-
tigen (HBsAg) is also a surrogate marker that can be used 
to monitor patients with CHB who are being treated, and 
HBsAg titer is related to HBV DNA levels (7).
Objectives
Using serum HBsAg concentration as a marker of HBV 
replication level in hepatitis B patients, we determined 
whether quantitative HBsAg correlates with hepatitis B 
virus (HBV) DNA levels in CHB in Iran.
Patients and Methods
This descriptive analytical study (cross-sectional) was 
performed to determine the correlation of serum HBSAg 
level and quantitative HBV DNA level in patients with 
chronic hepatitis B in the Department of Gastroenterol-
ogy and Hepatology, Imam Reza Hospital, Mashhad, Iran. 
All CHB patients who were HBsAg-positive for more than 
6 months and referred by a hepatologist to a qualified vi-
rology laboratory in Mashhad to undergo HBV DNA assay,  
were enrolled and selected by nonrandom sampling.
After the purpose of research was explained and in-
formed consent was obtained, samples were drawn and 
HBsAg, HCV Ab, HDV Ab, HBeAg, AST, and ALT levels were 
measured. Those who were positive for antibodies to HCV 
and HDV were excluded.HBV DNA was measured by real-
time PCR, and based on the detection limits, viral loads 
that were less than 100 was considered undetectable and 
excluded. ALT levels were measured by ELISA. Serum HB-
sAg was quantified by electrochemiluminescence assay 
(Roche Diagnostic), wherein HBsAg was expressed in IU/
ml. One hundred fifteen patients with chronic hepatitis 
B with HBeAg positive or negative were enrolled, 14 of 
whom were HDV-positive; and totally we excluded 4 pa-
tients due to missing data. SPSS 16 was used to analyze 
the data. Spearman correlation coefficient was used to 
correlate serum levels of HBsAg and HBV DNA levels. P ≤ 
0.05 was considered significant.
Results
Statistical Analysis
Fourteen patients (12%) with CHB were HDV-positive and 
excluded. Ninety-seven of 115 patients with CHB were in-
cluded; 70 were male (72%) and 27 were female(28%). The 
mean age was 39 ± 11 years. Eighty-five CHB patients were 
HBeAg-negative (87%) and 12 (13%) were HBeAg-positive. 
By Kolmogorov-Smimovtest, the distribution of HBsAg ti-
ters was normal and irregular for HBV DNA levels, HBeAg 
titer, AST, and ALT. Mean HBsAg level was 4021 ± 2305 IU/
ml;mean AST level was 54 ± 94 U/L and mean ALT was 62 ± 
84 U/L. Mean HBV DNA level was 4.69×106 ± 1.839× 107 copy/
ml (Figure 1).By Mann-Whitney test, HBSAg titer differed 
significantly between HBeAg-positive and -negative pa-
tients (P = 0.001). In 12 HBeAg-positive patients, less than 
25% had HBsAg titer = 1088 (Q1 = 1088) and HBsAg titer in 
25-50% of patients (Q2) = 2030 and in more than 75% of 
patients (Q3), HBsAg titer were =3143 IU/ml and in 72 pa-
tients with HBeAg negative, HBsAg titer were in Q1= 2349, 
Q2 = 4369, and Q3 = 6108 IU/ml (Figure 2).
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Figure 1. HBsAg titer in CHB (Mean = 3962.63, Std. Dev. = 2250.078, N = 82)Hepat Mon. 2011;11(5):342-345
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HBV DNA level also differed significantly between 
HBeAg-positive and negative patients (P = 0.009). HBV 
DNA level in HBeAg-positive subjects was Q1: 8.65×10³, Q2: 
9.02 ×105 and Q3: 8.38×107 and in HBeAg negatives were: 
Q1 (less than 25% of patients) = 515, Q2 (25-50% of patients) 
= 3350 AND Q3 (more than 75% of patients) = 7/60 ×10 4.By 
Spearman test, there was no significant correlation be-
tween HBsAg and HBV DNA (P = 0.606 and r = 0.53). After 
the data were split, this correlation remained insignifi-
cant inHBeAg-positive (P = 0.053 and r = -0.57) and-nega-
tive patients (P = 0.605 and r = 0.057). There was no sig-
nificant link between HBsAg level and ALT level (P = 0.45). 
HBV DNA levels correlated with ALT (P = 0.05, r = 0.19).
Discussion
We attempted to correlate quantitative HBsAg levels 
with HBV DNA level in an area in Iran that is predomi-
nantly HBeAg-negative, in which nearly all patients are 
infected by genotype D (8). HBsAg is a classical marker of 
infection with hepatitis B virus, and serological assays to 
detect HBsAg have guided its diagnosis. We hypothesized 
that HBsAg can be used to manage and monitor patients 
as well. On infection with HBV, closed circular DNA of HBV 
genome forms inside the nuclei of hepatocytes (9). DNA-
containing nucleocapsids become enveloped and are se-
creted into the blood (10). Hepatitis B virus ccc DNA is a 
template for viral replication, correlating robustly with 
levels of total intracellular HBV DNA, serum HBV DNA, 
and HBsAg (11). HBsAg quantification indirectly reflects 
the number of infected hepatocytes (12).
Chan, et al. observed that low pretreatment HBsAg is 
better than HBV DNA in predicting good responses to 
treatment (11). In another study of HBeAg-negative CHB, 
however, HBsAg correlated poorly with serum HBV DNA 
and did not correlate with intrahepatic ccc DNA or to-
tal HBV DNA. Quantitative Immunohistochemistry for 
hepatocyte HBsAg confirmed its relationship with viral 
replication only in HBeAg-positive patients (13). In our 
cases, 87% of whom were HBeAg-negative, there was no 
significant correlation between HBsAg level and HBV 
DNA level—even after subdivision into HBeAg-positive 
and -negative patients. Nevertheless, our analysis pro-
vides insight into the differences inHBsAg levels between 
HBeAg-positive and -negative patients, which appear to 
be affected by HBeAg status. HBV DNA levels were higher 
in HBeAg-positive patients, but HBsAg levels were higher 
in HBeAg-negative patients. In a previous study, we ob-
served patent differences in HBs levels based on HBeAg 
status (14).
Studies have measured HBsAg concentration during 
the treatment of HBeAg-negative patients. The lowest 
rate of Sustained Virological Response (SVR) with PEG 
interferon  was observed in those with genotype D(15), 
which experienced the smallest decline in HBsAg concen-
tration during treatment (16) and had the lowest chance 
of a sustained response with interferon-alpha(17). Thus, 
there are differences in the importance of quantitative 
HBsAg concentration for genotype D at baseline and dur-
ing treatment. All HBV isolates in Iranian patients are 
genotype D (8). We have an unusual subtype, "ayr," of the 
virus in Iran, which is not typical for HBV genotype D (18). 
Based on previous studies in throughout Iran, all CHB pa-
tients in Iran have genotype D; thus, there was no need to 
determine the genotype.
In our study, we found statistically significant differenc-
es in HBsAg and HBV DNA levels between HBeAg-positive 
and -negative patients, but our sample size was likely 
too small to observe any significant correlation between 
HBsAg and HBV DNA levels. Conversely, it can be due to 
genotype D in Iran. In HBeAg-positive patients, HBsAg 
correlated with serum HBV DNA, intrahepatic ccc DNA, 
and total HBV DNA, but these correlations were poor in 
HBeAg-negative cases (13). It appears thata cutoff value 
of 1500 IU/ml for serum HBsAg during treatment can be 
a predictor of seroconversion(19). In other studies, se-
rum HBsAg concentration has been used as a surrogate 
marker of HBV DNA in HBeAg-positive patients and those 
with high ALT; in their study, HBsAg titer predicted HBV 
DNA levels (20). In HBeAg-negative patients, HBsAg lev-
els were higher in patients with active disease than in 
those with inactive disease, and HBsAg remained stable 
in HBeAg-positive patients but tended to fall gradually in 
HBeAg-negative patients (21). In our study, after dividing 
patients by active and inactive CHB (based on ALT > 50 
and HBV DNA > 2000), we observed was no significant 
difference between active and inactive CHB, likely due to 
the small sample size. 
HBsAg titer can help differentiate active from inactive 
carriers. Single-point combined HBsAg and HBV DNA 
quantification provide the most accurate identification 
of inactive carriers (22). Thus, we need more studies with 
larger samples in active and inactive CHB to determine 
whether there is any correlation in this case.
There are 2 forms of HBsAg—one over intact virion, 
which includes small, medium, and large proteins in en-
velops and is related to viral infectivity, and another that 
HBs Ag titer
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Figure 2. Frequency of HBsAg titer in HBeAg-positive and -negative CHBHepat Mon. 2011;11(5):342-345
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exists as subviral particles in serum and is produced in 
great excess. These are predominantly S protein and, to 
a lesser extent, M and L protein; these are not infectious 
but are strongly immunogenic, stimulating antibody 
production. We propose that if we can detect 2 forms of 
HBsAg (over intact virion and subviral particle separately 
and quantitate them, we can determine the relationship 
between special forms of HBsAg and HBV DNA level.Based 
on our results, quantitative HBsAg level cannot be used 
as a surrogate marker for replicative state inHBeAg-neg-
ative patients in Iran. We recommend performing larger 
studies in Iran in different groups of CHB and patients 
who are being treated for CHB separately. HBeAg-nega-
tive patients have higher levels of HBsAg and lower levels 
of HBV DNA.   by electrochemiluminescence assay do not 
correlate significantly with HBV DNA level in HBeAg-posi-
tive or negative patients in Iran, necessitating additional 
studies to standardize quantification assays and define 
thresholds of HBsAg that have clinical predictive value.
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